Immunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years.
BACKGROUND: Measles vaccine in early infancy followed by a dose at 9 months of age protects against measles and enhances child survival through non-specific effects. Little is known of immune responses in the short or long term after booster doses. METHODS: Infants were randomized to receive measles...
| Hoofdauteurs: | , , , , , , , , , , , , , , |
|---|---|
| Formaat: | Journal article |
| Taal: | English |
| Gepubliceerd in: |
2012
|
| _version_ | 1826273558274244608 |
|---|---|
| author | Njie-Jobe, J Nyamweya, S Miles, D van der Sande, M Zaman, S Touray, E Hossin, S Adetifa, J Palmero, M Burl, S Jeffries, D Rowland-Jones, S Flanagan, K Jaye, A Whittle, H |
| author_facet | Njie-Jobe, J Nyamweya, S Miles, D van der Sande, M Zaman, S Touray, E Hossin, S Adetifa, J Palmero, M Burl, S Jeffries, D Rowland-Jones, S Flanagan, K Jaye, A Whittle, H |
| author_sort | Njie-Jobe, J |
| collection | OXFORD |
| description | BACKGROUND: Measles vaccine in early infancy followed by a dose at 9 months of age protects against measles and enhances child survival through non-specific effects. Little is known of immune responses in the short or long term after booster doses. METHODS: Infants were randomized to receive measles vaccine at 9 months of age (group 1) or 4 and 9 months of age (group 2). Both groups received a boost at 36 months of age. T-cell effector and memory responses using IFN-γ ELIspot and cytokine assays and antibody titres using a haemagglutination-inhibition assay were compared at various times. RESULTS: Vaccination at 4 months of age elicited antibody and CD4 T-cell mediated immune responses .Two weeks after vaccination at 9 months of age group 2 had much higher antibody titres than group1 infants; cell-mediated effector responses were similar. At 36 months of age group 2 antibody titres exceeded protective levels but were 4-fold lower than group 1; effector and cytokine responses were similar. Re-vaccination resulted in similar rapid and high antibody titres in both groups (median 512); cellular immunity changed little. At 48 months of age group 2 antibody concentrations remained well above protective levels though 2-fold lower than group 1; T-cell memory was readily detectable and similar in both groups. CONCLUSIONS: An additional early measles vaccine given to children at 4 months of age induced a predominant CD4 T-cell response at 9 months and rapid development of high antibody concentrations after booster doses. However, antibody decayed faster in these children than in the group given primary vaccination at 9 months of age. Cellular responses after 9 months were generally insignificantly different. |
| first_indexed | 2024-03-06T22:30:01Z |
| format | Journal article |
| id | oxford-uuid:57f86f50-b2ce-4001-b84f-574a88a1ad9c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:30:01Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:57f86f50-b2ce-4001-b84f-574a88a1ad9c2022-03-26T17:00:04ZImmunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:57f86f50-b2ce-4001-b84f-574a88a1ad9cEnglishSymplectic Elements at Oxford2012Njie-Jobe, JNyamweya, SMiles, Dvan der Sande, MZaman, STouray, EHossin, SAdetifa, JPalmero, MBurl, SJeffries, DRowland-Jones, SFlanagan, KJaye, AWhittle, HBACKGROUND: Measles vaccine in early infancy followed by a dose at 9 months of age protects against measles and enhances child survival through non-specific effects. Little is known of immune responses in the short or long term after booster doses. METHODS: Infants were randomized to receive measles vaccine at 9 months of age (group 1) or 4 and 9 months of age (group 2). Both groups received a boost at 36 months of age. T-cell effector and memory responses using IFN-γ ELIspot and cytokine assays and antibody titres using a haemagglutination-inhibition assay were compared at various times. RESULTS: Vaccination at 4 months of age elicited antibody and CD4 T-cell mediated immune responses .Two weeks after vaccination at 9 months of age group 2 had much higher antibody titres than group1 infants; cell-mediated effector responses were similar. At 36 months of age group 2 antibody titres exceeded protective levels but were 4-fold lower than group 1; effector and cytokine responses were similar. Re-vaccination resulted in similar rapid and high antibody titres in both groups (median 512); cellular immunity changed little. At 48 months of age group 2 antibody concentrations remained well above protective levels though 2-fold lower than group 1; T-cell memory was readily detectable and similar in both groups. CONCLUSIONS: An additional early measles vaccine given to children at 4 months of age induced a predominant CD4 T-cell response at 9 months and rapid development of high antibody concentrations after booster doses. However, antibody decayed faster in these children than in the group given primary vaccination at 9 months of age. Cellular responses after 9 months were generally insignificantly different. |
| spellingShingle | Njie-Jobe, J Nyamweya, S Miles, D van der Sande, M Zaman, S Touray, E Hossin, S Adetifa, J Palmero, M Burl, S Jeffries, D Rowland-Jones, S Flanagan, K Jaye, A Whittle, H Immunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years. |
| title | Immunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years. |
| title_full | Immunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years. |
| title_fullStr | Immunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years. |
| title_full_unstemmed | Immunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years. |
| title_short | Immunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years. |
| title_sort | immunological impact of an additional early measles vaccine in gambian children responses to a boost at 3 years |
| work_keys_str_mv | AT njiejobej immunologicalimpactofanadditionalearlymeaslesvaccineingambianchildrenresponsestoaboostat3years AT nyamweyas immunologicalimpactofanadditionalearlymeaslesvaccineingambianchildrenresponsestoaboostat3years AT milesd immunologicalimpactofanadditionalearlymeaslesvaccineingambianchildrenresponsestoaboostat3years AT vandersandem immunologicalimpactofanadditionalearlymeaslesvaccineingambianchildrenresponsestoaboostat3years AT zamans immunologicalimpactofanadditionalearlymeaslesvaccineingambianchildrenresponsestoaboostat3years AT touraye immunologicalimpactofanadditionalearlymeaslesvaccineingambianchildrenresponsestoaboostat3years AT hossins immunologicalimpactofanadditionalearlymeaslesvaccineingambianchildrenresponsestoaboostat3years AT adetifaj immunologicalimpactofanadditionalearlymeaslesvaccineingambianchildrenresponsestoaboostat3years AT palmerom immunologicalimpactofanadditionalearlymeaslesvaccineingambianchildrenresponsestoaboostat3years AT burls immunologicalimpactofanadditionalearlymeaslesvaccineingambianchildrenresponsestoaboostat3years AT jeffriesd immunologicalimpactofanadditionalearlymeaslesvaccineingambianchildrenresponsestoaboostat3years AT rowlandjoness immunologicalimpactofanadditionalearlymeaslesvaccineingambianchildrenresponsestoaboostat3years AT flanagank immunologicalimpactofanadditionalearlymeaslesvaccineingambianchildrenresponsestoaboostat3years AT jayea immunologicalimpactofanadditionalearlymeaslesvaccineingambianchildrenresponsestoaboostat3years AT whittleh immunologicalimpactofanadditionalearlymeaslesvaccineingambianchildrenresponsestoaboostat3years |